TITLE

Akzo Link with Pfizer Should Boost Pharma Unit

AUTHOR(S)
Alperowicz, Natasha; Scott, Alex
PUB. DATE
October 2003
SOURCE
Chemical Week;10/29/2003, Vol. 165 Issue 39, p32
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on an exclusive deal between Akzo Nobel's pharmaceutical business Organon and Pfizer in 2003. Value of the deal; Objective of the deal; Implication of the deal for Organon.
ACCESSION #
11240633

 

Related Articles

  • Akzo Nobel Signs Drug Pact With Pfizer.  // Chemical Market Reporter;10/27/2003, Vol. 264 Issue 14, p3 

    Announces the marketing partnership formed by pharmaceutical firms Organon and Pfizer Inc.

  • Organon hit by loss of patent.  // European Chemical News;12/23/2002, Vol. 77 Issue 2032, p7 

    Deals with the loss of the U.S. patent protection of Organon for its antidepressant Remeron in December 2002. Companies sued by Organon for launching generic alternatives to Remeron; Revenue earned from the sales of Remeron during the first quarter of 2002; Impact of the loss of the U.S. patent...

  • Akzo Nobel Strives to Boost Pharma With Pfizer Deal. Jarvis, Lisa // Chemical Market Reporter;11/3/2003, Vol. 264 Issue 15, p8 

    Reports on the agreement between the pharmaceutical firms Akzo Nobel Pharmaceutical and Pfizer Inc. in the U.S. Sales performance of Akzo Nobel; Benefits of the deal for the companies; Business strategies of Akzo Nobel.

  • Pharmaceuticals Industry Profile: the Netherlands.  // Pharmaceuticals Industry Profile: the Netherlands;Dec2007, p1 

    Presents a profile of the Pharmaceuticals industry in the Netherlands. Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the industry; Market forecasts; Demographics; Further reading.

  • Akzo Nobel expands US pharmaceutical facilities.  // Life Science Today;Oct2000, Vol. 1 Issue 5, p3 

    Reports on the expansion of Akzo Nobel BV's pharmaceutical facilities in the United States. Manufacture of a blood-clot preventing drug; Uses of the drug.

  • AKZO NOBEL'S PHARMA ON COURSE FOR DOUBLE-DIGIT GROWTH.  // Biotech Financial Reports;Nov2001, p5 

    Reports the financial performance of the Pharma Group Akzo Nobel. Focus on prescription pharmaceuticals; Plans of participating in the ranks of world-class pharmacies; Information on the annual growth and sales.

  • Pfizer, CDM clean up at Doctors' Choice. Arnold, Matthew // Medical Marketing & Media;Nov2007, Vol. 42 Issue 11, p18 

    The article announces that Pfizer Inc.'s Chantix and Organon Pharmaceutical USA Inc.'s Nuvaring professional advertisement has received the 2007 Doctors' Choice Awards from the Association of Medical Media.

  • American Dream. Smith, Davis N. // Pharmaceutical Executive;Jun2001, Vol. 21 Issue 6, p151 

    Reports that Organon, the pharmaceutical business unit of Akzo Nobel, will move its strategic functions from the Netherlands to the United States. Purpose of the move.

  • Akzo Nobel to grow drugs and coatings sectors. Alperowicz, Natasha // Chemical Week;3/4/1998, Vol. 160 Issue 8, p15 

    Focuses on the restructuring and earnings of Akzo Nobel. Company operations to be given much attention; Financial performance of the company in 1997; Why Akzo Nobel plan to transfer its industrial fibers operation into a joint venture with the Sabanci group; Targeted prescription drug sales by 2001.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics